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Abstract
Background: LAT1/4F2hc heterodimeric complex is a major route for the transport of large neutral essential amino
acids through the plasma membrane. Although it has been shown that LAT1/4F2hc is highly expressed in a variety
of human tumors including gliomas, and LAT1 over-expression is associated with glioma grade and poor prognosis
of glioma patients, the precise tissue location of LAT1/4F2hc in gliomas and the precise role of LAT1/4F2hc in
glioma biological features remain unclear.
Methods: In the current study, the expressions of LAT1, 4F2hc, CD34 and Ki-67 were investigated by
immunohistochemistry in 62 cases of human brain glioma; LAT1/4F2hc expression level, Ki-67 labeling index (Ki-67
LI) and microvessel density (MVD) were measured semi-quantitatively; and the correlation of LAT1/4F2hc expression
with histopathological features, Ki-67 LI and MVD in gliomas was further analyzed.
Results: The results showed that both LAT1 and 4F2hc were expressed in all examined specimens. LAT1 but 4F2hc
expression levels significantly correlated with the pathological grade and both expression levels significantly
correlated with Ki-67 LI of gliomas. We also demonstrated that both LAT1 and 4F2hc immunoreactivity were
observed in tumor cells as well as vascular endothelia; furthermore, the LAT1 expression level was markedly
associated with glioma MVD as well.
Conclusion: LAT1/4F2hc over-expression is closely correlates with the malignant phenotype and proliferation of
gliomas, and LAT1 was associates with glioma angiogenesis. LAT1/4F2hc, especially LAT1, may become a novel
potential molecular target for glioma biological therapy.
Background
In malignant tumor cells, a steady and sufficient sugar
and amino acid supply is necessary to maintain a high
degree of energy metabolism and protein synthesis for
rapid growth and continuous proliferation, and such a
supply is supported by the up-regulation of transporters
specialized for those nutrients [1]. In terms of glucose
supply, the over-expression of glucose transporter-1
(Glut-1) is related to increased glucose uptake in human
tumors [1]. Transporters for essential amino acids are
particularly important because they are indispensable for
protein synthesis to maintain cell integrity and cell cycle
progression. Among several amino acid transporters,
system L, a Na
+-independent amino acid transport sys-
tem, is a major route for providing cells with large neu-
tral amino acids, including branched or aromatic amino
acids, which contain most of the essential amino acids
[1,2]. Large (L)-type amino acid transporter 1 (LAT1) is
a membrane glycoprotein, subserving system L, and was
newly cloned in rat glioma C6 cells [3]. LAT1 is highly
expressed in brain capillaries that form the blood brain
barrier relative to other tissues [4]. LAT1 requires
another cell surface glycoprotein, the 4F2 heavy chain
(4F2hc), for its functional expression and forming a
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of 4F2 antigen or CD98 antigen, preferentially transports
large neutral amino acids, such as leucine, isoleucine,
valine, phenylalanine, tyrosine, tryptophan, methionine,
and histidine, which are essential for cell survival and
proliferation [1-3].
An increasing amount of research shows that LAT1/
4F2hc is over-expressed in a variety of human tumor
cell lines and tumor tissues, suggesting that LAT1/
4F2hc is implicated in the growth and proliferation of
multiple types of human tumor [1,2,5], including lung
cancer [6,7], breast cancer [8], esophageal carcinoma [9],
prostate cancer [10], uterine cervical carcinoma [11],
ovarian cancer [12], thymic carcinoma [13], oral cancer
[14], head and neck squamous cell carcinoma [15],
metastatic tumor [16], and so forth. For glioma, the
most common primary malignant neoplasm arising in
the central nervous system, at present, only a few
reports exist regarding the LAT1/4F2hc expression in
this kind of tumor [17,18]. The related data indicate
that LAT1/4F2hc is highly expressed in human gliomas,
and associated with glioma progression as well as the
poor prognosis of glioma patients [17]; furthermore,
treatment of 2-aminobicyclo-(2,2,1)-heptane-2-car-
boxylic acid (BCH), a system L selective inhibitor, exerts
significant cytotoxic effects, with reduced proliferation
and increased apoptosis rates in glioma cells with high
LAT1 expression [18]. Nevertheless, the exact tissue
location of LAT1/4F2hc in gliomas and the precise role
of LAT1/4F2hc in glioma malignant biological features
remain unclear. Therefore, we investigated systematically
the LAT1/4F2hc expression in 62 cases of human brain
glioma by immunohistochemistry, and further analyzed
the relation of LAT1/4F2hc expression with the glioma
histopathological grade, malignant proliferation and
angiogenesis in this study.
Methods
Patients and specimens
Sixty-two patients with gliomas treated at the Depart-
ment of Neurological Surgery of Kagawa University
from October 1995 to February 2010 were enrolled in
this study. All patients had received neither chemother-
apy nor radiotherapy before tumor surgical resection.
All specimens were obtained from their initial surgery.
Patients included 31 men and 31 women ranging in age
from 3 to 89 years (mean age: 51.4 ± 18.0, median: 52).
Histological subtypes and pathological grades of tumors
were defined according to the World Health Organiza-
tion (WHO) criteria in 2007, as follows: 4 cases with
grade I, all specimens were pilocytic astrocytomas; 14
cases with grade II, including 12 diffuse astrocytomas (2
gemistocytic astrocytomas), 1 ependymoma and 1 oli-
goastrocytoma; 13 cases with grade III, including 12
anaplastic astrocytomas and 1 anaplastic ependymoma;
31 cases with grade IV, all specimens were glioblasto-
mas. Eighteen cases were low grade gliomas, including
grade I and II; 44 cases were high grade gliomas, includ-
ing grade III and IV. The cellular proliferation activity
o ft h et u m o rw a sd e t e r m i n e db ym e a s u r i n gt h eK i - 6 7
labeling index (Ki-67 LI), which was obtained routinely
by immunohistochemical staining with anti-Ki-67 at the
Department of Pathology of Kagawa University.
Immunohistochemistry for LAT1, 4F2hc and CD34
Immunohistochemical staining was performed on paraf-
fin sections using the polymer-peroxidase method.
Briefly, the 3-μm thick sections were deparaffinized and
rehydrated routinely. For LAT1 and CD34 immunos-
taining, antigen retrieval was performed by boiling the
sections in 0.01 M citrate buffer (pH 6.0) in a micro-
wave oven for 10 and 15 minutes, respectively. For
4F2hc immunostaining, there was no need for antigen
retrieval. After the sections were rinsed in distilled
water, the endogenous peroxidase was inactivated with
3.0% hydrogen peroxide in distilled water for 10 minutes
at room temperature. After rinsing the sections in phos-
phate-buffered saline (PBS, pH 7.4), the nonspecific
binding site was blocked with 10% normal goat serum
for 20 minutes at room temperature. The blocking
serum was discarded and then the primary antibodies
were added directly. Rabbit antihuman LAT1 polyclonal
antibody (Trans Genic, Kumamoto, Japan) was diluted
to 1:12.5, rabbit antihuman 4F2hc polyclonal antibody
(Trans Genic) 1:8, and rabbit antihuman CD34 mono-
clonal antibody (Abcam, Cambridge, UK) 1:150 in PBS,
respectively. The sections were incubated for 2 hours at
room temperature. After rinsing in PBS, goat antirabbit
polymer-peroxidase complex (EnVision+/HRP; DakoCy-
tomation, Glostrup, Denmark) was added, and the sec-
tions were incubated for 30 minutes at room
temperature. After rinsing with PBS, the peroxidase
reaction was performed using 0.02% 3,3’-diaminobenzi-
dine tetrahydrochloride (DAB; Sigma-Aldrich, St. Louis,
MO, USA) in PBS containing 0.01% hydrogen peroxide
for 3-15 minutes at room temperature. The sections
were counterstained with Mayer’s hematoxylin, then
dehydrated and mounted. The primary antibodies were
substituted with PBS as a negative control for each
section.
Evaluation of staining results of LAT1 and 4F2hc
The immunoreactivity of LAT1 and 4F2hc in tumor
cells was graded semi-quantitatively from (-) to (+++)
on the basis of both the percentage of positive cells and
the intensity of staining, almost according to the meth-
ods described by Nawashiro et al. [17]. This grading
procedure was performed by a blinded observer (HNZ)
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clinical data in all the tumor specimens. Briefly, in the
most strongly stained tumor cell area of each section,
more than 1,000 tumor cells were observed in high-
powered fields at × 400 magnification. The percentage
of LAT1 and 4F2hc positive cells was calculated by
dividing the number of positively stained tumor cells by
the total number of tumor cells observed. The cases
that contained equal to or less than 50% positive cells
were called less/equal 50% staining, and those that con-
tained more than 50% positive cells were called over
50% staining. The intensity of staining was recorded as
negative, weak or strong respectively. Because of the
heterogeneity of staining intensity of the tumor cells,
the intensity of staining of each case was determined
according to the staining intensity of most cells. The
cases that contained a weak less/equal 50% staining or
unstained specimens were considered negative (-), weak
over 50% staining (+), strong less/equal 50% staining (+
+), and strong over 50% staining (+++). Immunoreactiv-
ity of LAT1 and 4F2hc in tumor vessel endothelia was
graded semi-quantitatively from (-) to (+++) as well, on
the basis of the number of stained microvessels (NMV).
Briefly, in areas of the most intensely stained vascular
endothelial cells, individual microvessels were counted
on three to five × 200 magnification fields. Any
endothelial cell or endothelial cell cluster was consid-
ered a single countable microvessel. NMV was expressed
as the mean value of the absolute number of microves-
sels per × 200 field for each case. The cases in which
NMV ≤1 were considered no staining microvessel (-), 1
<N M V≤15 few staining microvessels (+), 15 < NMV
≤30 more staining microvessels (++), and NMV > 30
abundant staining microvessels (+++). The highest
immunoreactivity grades of LAT1 and 4F2hc in tumor
cells or in tumor vessel endothelia were considered their
respective ultimate immunoreactivity grades in each
case.
Evaluation of microvessel density (MVD)
The microvessel density (MVD) of gliomas was mea-
sured according to the method described by Zhen et al.
[19]. Briefly, in areas of the most intense CD34 positive
neovascularization, individual MVDs were made on a ×
200 magnification field. Any endothelial cell or endothe-
lial cell cluster was considered a single countable micro-
vessel. MVD was expressed as the absolute number of
microvessels per × 200 field for each case.
Statistical analysis
Data were presented as mean, range, and standard
deviation (SD). The expression of LAT1 and 4F2hc
scores in relation to tumor pathology was evaluated
using c
2-test. The correlations between expression levels
of LAT1 and 4F2hc with clinical data, Ki-67 LI and
MVD were analyzed using the non-parametric Spear-
man’s rank correlation. Differences of Ki-67 LI and
MVD in different pathological grade groups were com-
pared using one-way analysis of variance (ANOVA). Dif-
ferences of Ki-67 LI and MVD in benign and malignant
glioma groups were compared using Student’s t test.
Probability values of < 0.05 were considered statistically
significant. All the statistical analysis was performed
using the SPSS 16.0 package.
Ethics Statement
The use of human brain tumor samples for this study
was approved by the Kagawa University, Faculty of
Medicine Human Subject Ethical committees and fol-
lowed the guidelines of the declaration of Helsinki,
Informed consent was obtained from all patients. Only
samples that were initially taken for diagnostic purpose
were secondary used for the present study.
Results
Qualitative immunohistochemical analysis for LAT1 and
4F2hc
Both LAT1 and 4F2hc were expressed in all the glioma
tissues examined (Table 1). LAT1 immunoreactivity was
mainly observed in the vascular endothelium and the
tumor cytoplasm, as well as the tumor plasma mem-
brane (Figure 1A-E). 4F2hc was predominantly
expressed in the tumor cytoplasm and the plasma mem-
brane, as well as in the vascular endothelium (Figure
1G-K). In general, the intensity of 4F2hc immunostain-
ing was higher than that of LAT1 in the tumor tissues.
In 11 cases of normal brain tissue adjacent to the
tumor, there was only negligible LAT1 and 4F2hc
Table 1 LAT1/4F2hc expression, Ki-67 LI, and MVD in
human brain gliomas
Glioma LAT1 (no.) 4F2hc (no.) Ki-67 LI (%) MVD (no.)
+ ++ ++ +++
Grade
I 1 2 1 1 2 1 1.4 ± 0.8 64.3 ± 15.4
II 6 4 4 3 7 4 3.4 ± 1.9 53.4 ± 54.4
III 5 3 5 2 4 7 13.1 ± 9.4 58.0 ± 29.2
IV 1 4 26 1 7 23 37.2 ± 18.4 77.6 ± 39.9
P value* 0.002 0.06
Degree
Low 7 6 5 4 9 5 2.9 ± 1.9 55.8 ± 48.2
High 6 7 31 3 11 30 30.1 ± 19.6 71.8 ± 37.8
P value* 0.008 0.01
Total 13 13 36 7 20 35 22.2 ± 20.6 67.2 ± 41.4
Note: LAT1: large (L)-type amino acid transporter, 4F2hc: 4F2 heavy chain, Ki-
67 LI: Ki-67 labeling index, MVD: microvessel density
*P value was evluated using c
2-test
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Page 3 of 8Figure 1 LAT1 and 4F2hc expression in human brain gliomas and normal brain tissues. Upper two panels (A-F) for LAT1 expression and
lower two panels (G-L) for 4F2hc expression. (A) Pilocytic astrocytoma (WHO grade I) with few LAT1 staining microvessels (graded +). (B)
Fibrillary astrocytoma (WHO grade II) with more LAT1 staining microvessels (graded ++). (C) Anaplastic astrocytoma (WHO grade III) with strong
over 50% LAT1 staining in the cytoplasm and plasma membrane of tumor cells (graded +++). (D) Glioblastoma (WHO grade IV) with strong over
50% LAT1 staining in cytoplasm and plasma membrane of tumor cells and more LAT1 staining microvessels (graded +++). (E) Glioblastoma
(WHO grade IV) with strong over 50% LAT1 staining in the cytoplasm and plasma membrane of tumor cells and abundant LAT1 staining
microvessels (graded +++). (F) Normal brain tissue adjacent to the glioblastoma (D) with only negligible LAT1 staining. (G) Pilocytic astrocytoma
(WHO grade I, the same specimen as shown in A) with weak over 50% F2hc staining in the cytoplasm and plasma membrane of tumor cells
(graded +). (H) Gemistocytic astrocytoma (WHO grade II) with strong less/equal 50% 4F2hc staining in the cytoplasm and plasma membrane of
tumor cells (graded ++). (I) Anaplastic astrocytoma (WHO grade III) with strong over 50% 4F2hc staining in the plasma membrane and
cytoplasm of tumor cells (graded +++). (J) Glioblastoma (WHO grade IV) with strong over 50% 4F2hc staining in the cytoplasm and plasma
membrane of tumor cells and more 4F2hc staining microvessels (arrow heads, graded +++). (K) Glioblastoma (WHO grade IV, the same
specimen as shown in E) with strong over 50% 4F2hc staining in the cytoplasm and plasma membrane of tumor cells (graded +++). (L) Normal
brain tissue adjacent to the glioblastoma (E and K) without obvious 4F2hc staining. Immunohistochemical polymer-peroxidase method was
used, immunoreactions were visualized with 3,3’-diaminobenzidine tetrahydrochloride (DAB) and nuclear counterstaining was performed with
Mayer’s hematoxylin. Original magnification × 400, and all bars = 20 μm.
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and 4F2hc in normal brain tissues was similar to that in
the tumor tissues (Figure 1F, L). There was a significant
positive correlation between the LAT1 expression level
and 4F2hc expression level in this series of glioma speci-
mens (r = 0.319, P = 0.011).
Correlation of LAT1 and 4F2hc staining with
histopathological features
Although the LAT1 immunoreactivity enhanced signifi-
cantly with the glioma pathological grade ascending (P
= 0.002), the 4F2hc immunoreactivity did not correlated
with the glioma grade (P = 0.06) (Table 1). The expres-
sion levels of both LAT1 and 4F2hc in high grade
glioma tissues were significantly higher than those in
low grade glioma tissues (P = 0.008 and P =0 . 0 1 ,
respectively) (Table 1). However, there was no signifi-
cant relation between LAT1 and 4F2hc expression with
age (r = 0.156, P = 0.226; r =0 . 1 9 5 ,P = 0.142) and sex
(r =0 . 0 1 3 ,P = 0.919; r = 0.093, P = 0.621) of this series
of glioma patients.
Correlation of LAT1 and 4F2hc staining with Ki-67 LI
Ki-67 LI ranged from 1% to 75% with mean 22.2 ±
20.6% in this series of glioma specimens (Table 1). Ki-67
LI increased significantly with the glioma pathological
grade ascending (F = 25.328, P = 0.000), as well as Ki-
67 LI in high grade glioma tissues being significantly
higher than that in low grade glioma tissues (t = 5.842,
P = 0.000). There was a significant positive correlation
between the immunoreactivity of both LAT1 and 4F2hc
and Ki-67 LI (r = 0.370, P = 0.003; r = 0.375, P = 0.003)
(Figure 2).
Correlation of LAT1 and 4F2hc staining with MVD
MVD ranged from 8 to 193 with mean 67.2 ± 41.4 in
this series of glioma specimens (Table 1). There was no
significant difference in MVD among the different
glioma grades (F =1 . 4 3 2 ,P = 0.243). Although MVD in
high grade glioma tissues was slightly higher than that
in low grade glioma tissues, there was no statistical sig-
nificance (t = 1.398, P = 0.167). There was a significant
positive correlation between the LAT1 immunoreactivity
and MVD (r = 0.472, P = 0.000), however not for 4F2hc
(r = 0.160, P = 0.214) (Figure 3).
Discussion
In the present research, we showed that both LAT1 and
4F2hc were over-expressed in human brain gliomas;
however, both of them were only negligibly expressed in
adjacent normal brain tissues, suggesting that LAT1 and
4F2hc co-expression is closely associated with the for-
mation and development of gliomas. These results were
almost in agreement with previous reports [17,18].
Although some previous reports have shown that LAT1
and 4F2hc are co-expressed in brain tissue vascular
endothelia of mouse, rat, and cattle [20-22], to date,
there is no research showing that LAT1 and 4F2hc are
co-expressed in vascular endothelia of human normal
tissues or human tumor tissues. To the best of our
knowledge, this is the first report demonstrating that
both LAT1 and 4F2hc were expressed in vascular
endothelia of human brain gliomas, indicating that the
LAT1/4F2hc complex plays an important role in large
neutral amino acids permeating the blood-brain barrier
(BBB) in human brain gliomas. In our previous research
with less glioma samples, although the LAT1 immunor-
eactivity was clear in vascular endothelia in glioma tis-
sues, the 4F2hc immunoreactivity was not obvious [23].
One possible reason was that the 4F2hc immunoreactiv-
ity in glioma cells was intensive, so that the 4F2hc
immunoreactivity in vascular endothelia was hidden. In
this study, although both LAT1 and 4F2hc were
expressed in both tumor cells and vascular endothelia of
Figure 2 Correlation of LAT1 and 4F2hc expression with Ki-67 LI in human brain gliomas.( A) A significant positive correlation was
observed between LAT1 expression and Ki-67 LI. (B) A significant positive correlation was also observed between 4F2hc expression and Ki-67 LI.
Spearman’s rank correlation test was used.
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between LAT1 expression and 4F2hc expression, the
expression level and location of LAT1 and 4F2hc was
not completely parallel, i.e. in general, the 4F2hc immu-
nostaining was more intensive than LAT1 immunostain-
ing in glioma tissues, and moreover, LAT1
immunoreactivity was markedly stronger than 4F2hc
immunoreactivity in vascular endothelia. On the con-
trary, 4F2hc immunoreactivity was markedly stronger
than LAT1 immunoreactivity in tumor cells, and these
results suggest there are different expression regulation
mechanisms for LAT1 and 4F2hc [1,2,5].
In the present study, LAT1 but 4F2hc expression
levels significantly correlated with the glioma pathologi-
cal grade, although they were obviously higher in high
grade gliomas than in low grade gliomas. Moreover,
both LAT1 and 4F2hc expression levels were strongly
associated with Ki-67 LI of glioma tissues. These results
indicate that LAT1/4F2hc may play an important role in
the malignant proliferation and progression of high-
grade gliomas [17,18]. The up-regulated expression of
LAT1/4F2hc may benefit by providing tumor cells with
essential amino acids for high levels of protein synthesis
associated with cell activation or hormonal stimulation
and also to support rapid growth or excessive prolifera-
tion [1,2]. In light of both LAT1 and 4F2hc expression
in vascular endothelia, it is reasonable to further analyze
whether there is a certain correlation between LAT1/
4F2hc expression and angiogenesis. We demonstrated
here, also for the first time, that the LAT1 expression
level was significantly associated with MVD, although
unlike that for 4F2hc expression, in human brain glio-
mas. These results indicate that LAT1 may play a key
role in the neovascularization of gliomas. Therefore, it is
involved in multiple aspects for the mechanism of LAT1
promoting the growth and proliferation of glioma cells,
that is to say, LAT1 can transport essential amino acids
not only from the extracellular fluid to intracellular
pool, but also from the tumor microvessel to extracellu-
lar matrix [20-22].
In this series of glioma specimens, Ki-67 LI markedly
correlated with the glioma pathological grade, and Ki-67
LI in high grade glioma tissues was significantly higher
than that in low grade glioma tissues, suggesting that
tumor cell proliferative activity obviously enhances with
the increase in the glioma pathological grade, which was
in agreement with the previous reports [19]. However,
there was no statistically significant correlation between
the MVD and glioma pathological grade, although MVD
in high grade glioma tissues was slightly higher than
that in low grade glioma tissues, and if grade I pilocytic
astrocytomas are excluded, there was an increasing ten-
d e n c yo fM V Dw i t ht h eg l i o m ap a t h o l o g i c a lg r a d e
ascending, suggesting that the pilocytic astrocytoma is a
very specific glioma subtype with better prognosis, the
lowest pathological grade and very low Ki-67 LI, but
abundant neovascularization; also indicating Ki-67 LI
may more objectively reflect the malignant degree of
gliomas compared with MVD. Interestingly, the LAT1
expression level significantly correlated with not only
Ki-67 LI but also MVD in this series of glioma speci-
mens, perhaps indicating that the LAT1 expression level
can display more biological features of gliomas, and
LAT1 may become a novel valuable molecular marker
for gliomas.
A c c o r d i n gt oo u rf i n d i n g s ,L A T 1 / 4 F 2 h cw a so v e r -
expressed in human brain gliomas, and their over-
expression was associated with the malignant progres-
sion and excessive proliferation of gliomas; furthermore,
LAT1 may also play some roles in glioma angiogenesis.
Combining the previous related reports that LAT1 over-
expression predicts short survival of glioma patients
[17], blocking the activity of LAT1 with a system L
selective inhibitor can markedly inhibit the growth of
Figure 3 Correlation of LAT1 and 4F2hc expression with MVD in human brain gliomas.( A) A significant positive correlation was observed
between LAT1 expression and MVD. (B) No significant correlation was observed between 4F2hc expression and MVD. Spearman’s rank
correlation test was used.
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cells [18], as well as the expression distribution features
of LAT1/4F2hc whereby LAT1 is only definitely
expressed in few human normal tissues or organs
including the placenta, testis and bone marrow, whereas
4F2hc is ubiquitously expressed in various human nor-
mal tissues or organs [5]. We consider that LAT1 may
become a better potential molecular target for glioma
biological therapy compared with 4F2hc.
Conclusions
LAT1/4F2hc over-expression is correlates with the
malignant progression and proliferation of high-grade
gliomas, and LAT1 also associates closely with glioma
angiogenesis. LAT1/4F2hc, especially LAT1, may
become a novel potential molecular target for glioma
biological therapy.
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